Physician

Daulath Singh, MD

According to 2025 Medicare claims, Daulath Singh, MD (NPI: 1568882876) practices medical oncology in the Des Moines-West Des Moines, IA market, with the plurality of this provider's patient population coming from Polk, IA. This provider's primary affiliated billing organization is THE IOWA CLINIC PC (NPI: 1346233178; TIN: 421420077) and primary practice location at 50266-9998. Singh is affiliated with the Cotton-O'Neil ACO llc (ACO ID: A2506), CoreHealth Alliance LLC (ACO ID: A5645), and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 623 traditional Medicare patients, billed 45,697 HCPCS/CPT codes, and received $906,252 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 893 prescription claims across 238 beneficiaries totaling $878,744 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 71 claims. Open Payments data shows 3 records totaling $3,076. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $34,195 to $906,252. Similarly, Part D prescription costs have risen steadily, from $39,943 to $878,744. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	160	607	$34,195
2021	313	1,838	$97,370
2022	436	2,581	$128,261
2023	640	3,348	$144,501
2024	623	45,697	$906,252

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	53	461	$39,943
2016	55	522	$61,231
2017	52	463	$22,716
2018	15	75	$890
2019	N/R	18	$14,318
2020	55	186	$164,493
2021	129	817	$716,107
2022	180	1,145	$1,153,958
2023	243	1,410	$1,325,136
2024	238	893	$878,744

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	63	$6,523
2022	N/R	N/R	N/R
2023	N/R	71	$7,502
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	255	400	$80
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	214	226	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	158	246	$12
36415	Insertion of needle into vein for collection of blood sample	280	443	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	52	201	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	20	480	$258,111
Eliquis	Apixaban	43	1,392	$27,485
Xarelto	Rivaroxaban	18	540	$9,743
Savaysa	Edoxaban Tosylate	11	330	$4,556
Letrozole	Letrozole	62	4,714	$1,875

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$76	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$3,000	Celgene Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daulath Singh, MD?

Tedicare shows public-source Medicare data for Daulath Singh, MD (NPI 1568882876), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daulath Singh, MD have ACO affiliation data?

Daulath Singh, MD is shown with ACO affiliation data for Cotton-O'Neil ACO llc (MSSP, ACO ID A2506), CoreHealth Alliance LLC (MSSP, ACO ID A5645), and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Daulath Singh, MD?

Daulath Singh, MD is linked to THE IOWA CLINIC PC (billing NPI 1346233178) in the available physician profile data.

Does Daulath Singh, MD have Open Payments data?

Daulath Singh, MD has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.